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ABSTRACT
Human leukocyte antigen (HLA) DR15 is associated with autoimmune cytopenia in patients with aplastic
anemia, myelodysplastic syndrome, and paroxysmal nocturnal hemoglobinuria. Presence of this antigen also
predicts response to immunosuppressive treatment. If DR15 expression on hematopoietic cells also favors
induction of immune responses in an allogeneic setting, a lower relapse rate after hematopoietic stem cell
transplantation (HSCT) might result through an enhanced graft-versus-leukemia effect. We retrospectively
analyzed outcome of HLA-identical sibling HSCT in 192 consecutive patients with acute or chronic leukemia
or non-Hodgkin lymphoma. Patients carrying the DR15 antigen had a higher estimated 5-year overall survival
(76%) than did DR15-negative patients (55%; P  .04). Improved survival for DR15 patients was due to a
significant decrease in death from relapse (5% for DR15 versus 24% for DR15; P  .02), whereas no
difference was seen for rates of transplant-related mortality (19% and 21%, respectively; P  .76). Findings
were confirmed by multivariate analyses. Our results show an association of DR15 with a decreased risk of
disease relapse and improved survival after HSCT for leukemia or non-Hodgkin lymphoma. This adds to the
growing list of links between DR15 and immune reactions in hematopoiesis.
© 2006 American Society for Blood and Marrow Transplantation
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aNTRODUCTION
Autoimmune bone marrow hypoplasia and ensu-
ng peripheral blood cytopenia are features of several
ifferent hematologic disorders, among them aplastic
nemia (AA) and subgroups of myelodysplastic syn-
rome (MDS) and paroxysmal nocturnal hemoglobin-
ria. For AA, as for many other autoimmune disor-
ers, an association to an HLA constellation, ie, the
resence of the serologically deﬁned DR2 antigen
1,2] and later its serologic DR15 split and genetic
RB1*15 allele counterpart [3], were identiﬁed. Fur-
her evidence for a role of DR15 in the pathogenesis
f the disease comes from the fact that response rates Ho immunosuppressive therapy are higher in patients
xpressing the DR15 antigen than in those who do not
4-6]. Recent studies in patients with MDS and par-
xysmal nocturnal hemoglobinuria—2 diseases intri-
ately related to AA, with subgroups presenting a
linical picture difﬁcult to distinguish from AA—have
onﬁrmed DR15 as a marker of susceptibility for the
isease and for response to immunosuppressive treat-
ent [5,7,8]. This association of DR15 with autoim-
une cytopenia raises the possibility that the DR15
olecule preferentially presents an autoantigen on
ematopoietic precursor cells evoking an immune re-
ction and eventually causing bone marrow aplasia.
igh antibody titers to a candidate autoantigen pre-
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M. Stern et al.1170ented by DR15 have recently been described in pa-
ients with AA or MDS [9].
T lymphocyte-mediated graft-versus-leukemia re-
ction after allogeneic hematopoietic stem cell trans-
lantation (HSCT) offers a unique setting to study
mmunologic effects against hematopoietic precursor
ells. Several retrospective studies that assessed the
nﬂuence of HLA antigens on outcome after HSCT
ave found rates of acute graft-versus-host disease
aGVHD) being altered by HLA antigens, but no
ffect has been reported in rates of relapse or overall
urvival [10,11]. A recent report looking speciﬁcally
or an effect of DR15 described a decreased incidence
f GVHD in patients expressing the DR15 antigen
ompared with those who do not, showing that pres-
nce of DR15 might inﬂuence donor-versus-recipient
lloreactivity after HSCT [12].
We hypothesized that, if the DR15 antigen confers a
referential susceptibility to T cell-mediated (auto-)im-
unity, an increased alloimmune effect might be seen
fter HSCT, resulting in a lower relapse rate after
SCT for patients carrying the DR15 antigen. We
herefore analyzed the outcome of patients treated with
llogeneic HLA-identical sibling HSCT for malignant
ematopoietic disorders with respect to presence or ab-
ence of the DR15 antigen.
ETHODS
tudy Design
In a single-center cohort study, we retrospectively
nalyzed overall mortality, causes of death, and inci-
ence/severity of aGVHD and chronic GVHD
cGVHD) after T cell-replete HLA-identical sibling
ransplantation in 192 consecutive patients who un-
erwent transplantation between 1989 and 2004 for
cute myeloid and lymphoblastic leukemias, chronic
yeloid leukemia, and chronic lymphocytic leuke-
ia/non-Hodgkin lymphoma. All patients had un-
ergone HLA-DRB1 molecular typing. Outcome of
atients expressing the DR15 antigen was compared
ith that of patients negative for DR15.
LA Typing
Patients and their donors were HLA typed at the
ational Reference Laboratory for Histocompatibil-
ty (Geneva, Switzerland) or in the Hematology Lab-
ratory of the University Hospital (Basel, Switzer-
and). DRB1* typing by polymerase chain reaction
equence-speciﬁc primer or polymerase chain reaction
equence-speciﬁc oligonucleotide probe hybridization
sing commercially available reagents was performed
n all patients.
atients
Patient characteristics according to DR15 status
re presented in Table 1. No signiﬁcant differences cere seen between patients positive or negative for the
R15 antigen.
Approximately 50% of patients underwent trans-
lantation for acute leukemia, and the other 50% had
hronic myeloid leukemia or chronic lymphocytic
eukemia/non-Hodgkin lymphoma. Disease stage was
eﬁned as early in the following circumstances: acute
eukemia in ﬁrst remission or chronic myeloid leuke-
ia in chronic phase. All other disease stages were
lassiﬁed as advanced. Patients with acute myeloid or
ymphoid leukemia were additionally stratiﬁed ac-
ording to cytogenetical abnormalities, identiﬁed by
onventional cytogenetics or molecular testing for fu-
ion transcripts: for acute myeloid leukemia, the pres-
nce of t(15;17), t(8;21), or inv(16) was considered as
onferring a low risk of relapse; deletions involving
he short arm of chromosome 5 or 7, inv(3), and complex
bnormalities were considered as high risk; patients with
ormal karyotype or carrying any other transloca-
ion were considered at intermediate risk [13]. For
cute lymphoblastic leukemia, the translocations
(9;22), t(4;11), and t(1;19) were considered high
isk; presence of a hyperdiploid karyotype or of the
ranslocation t(12;21) were considered low risk;
ther translocations or a normal karyotype were
onsidered intermediate risk [14].
All patients received T lymphocyte-replete grafts.
eripheral blood was the stem cell source in 66% of
atients. Conditioning consisted of cyclophosphamide
nd total body irradiation (12 Gy) with or without
P16 in most patients. Conditioning was myeloabla-
ive except for patients treated with ﬂudarabine and
ingle-dose total body irradiation (2 Gy). GVHD pro-
hylaxis after transplantation consisted of cyclosporin
with or without methotrexate except for patients
eceiving nonmyeloablative conditioning, where cy-
losporin A plus mycophenolate mofetil was adminis-
ered instead.
ontrols
Two German cohorts [15,16] and 1 Swiss cohort
17] of healthy individuals (routine blood donors)
erved as controls for estimation of the frequency of
LA-DR15 in the region of origin of our patients.
ndpoints and Definitions
Endpoints were overall survival, disease-related
ortality (DRM), which was deﬁned as death from
elapse/disease progression after transplantation, and
ransplant-related mortality (TRM), which was de-
ned as death from any nonrelapse cause after trans-
lantation. Incidence and severity of aGVHD and
GVHD were secondary endpoints and graded ac-
ording to established criteria [18].
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HLA-DR15 Reduces Relapse Risk after HSCT 1171tatistics
Comparison of cohorts was performed using Pear-
on chi-square or Fisher exact test for categorical and
tudent t test or Mann-Whitney test for continuous
ariables. Overall survival was estimated using the
aplan-Meier method [19], and comparison of co-
orts was performed by log-rank test. Cumulative
ncidences of DRM and TRM were calculated by
reating TRM and DRM as competing risks.
For aGVHD, cumulative incidences were calculated
y treating death from any cause as a competing risk.
For multivariate analysis of survival, Cox propor-
ional hazard models were used [20]. Competing risk
roportional hazard models by Fine and Gray [21]
ere used for multivariate analysis of DRM and
RM. DR15 status was forced into all models; disease,
isease stage, cytogenetics, patient age, conditioning
able 1. Patient Characteristics
nderlying disease
Acute lymphoblastic leukemia
Acute myeloid leukemia
Chronic myeloid leukemia
Chronic lymphocytic leukemia/non-Hodgkin lymphoma
isease stage
Early
Advanced
ytogenetics*
Good risk
Intermediate risk
Bad risk
Not done or not informative
onor/recipient sex
Male/male
Male/female
Female/male
Female/female
atient age at transplantation, median (range)
ear of transplantation, median (range)
tem cell source
Bone marrow
Peripheral blood
onditioning
Myeloablative
Cyclophosphamide/TBI
Cyclophosphamide/VP16/TBI
Busulfan/cyclophosphamide
Other
Nonmyeloblative
Fludarabine/TBI
VHD prophylaxis
Cyclosporine
Cyclosporine  methotrexate
Cyclosporine  mycophenolate
BI indicates total body irradiation; GVHD, graft-versus-host dise
Patients with acute lymphoblastic or acute myeloid leukemia onlyegimen, donor/recipient sex combination, GVHD 1rophylaxis, and time of transplantation were incor-
orated by using forward stepwise inclusion of vari-
bles with a signiﬁcance level of .05. Variables in-
luded in the ﬁnal models were tested by using a
ime-dependent covariate method to determine
hether the proportional hazards assumption was
et.
Statistical analyses were carried out with SPSS
2.0 (SPSS Inc, Chicago, Ill) and R 2.2.1 (http://
ww.r-project.org).
ESULTS
revalence of HLA-DR15 in Patients and Controls
The mean prevalence of HLA-DR15 was similar
n the 3 control cohorts of normal individuals: 34 of
n (%)
P
DR15 Negative
(n  149)
DR15 Positive
(n  43)
53 (35.6) 15 (34.9) .39
38 (25.5) 9 (20.9)
36 (24.2) 8 (18.6)
22 (14.8) 11 (25.6)
66 (44.3) 17 (39.5) .58
83 (55.7) 26 (60.5)
8 (8.8) 1 (4.2) .95
56 (61.5) 16 (66.7)
15 (16.5) 4 (16.7)
12 (13.2) 3 (12.5)
44 (29.5) 18 (41.9) .27
29 (19.5) 10 (23.3)
47 (31.5) 8 (18.6)
29 (19.5) 7 (16.3)
40.1 (3-63) 40.3 (4-55) .65
998 (1989-2004) 1999 (1992-2004) .31
52 (34.9) 12 (27.9) .39
97 (65.1) 31 (72.1)
17 (11.4) 6 (14.0) .84
88 (59.1) 24 (55.8)
7 (4.7) 1 (2.3)
11 (7.4) 5 (11.6)
26 (17.4) 7 (16.3)
30 (20.1) 9 (20.9) .98
93 (62.4) 27 (62.8)
26 (17.4) 7 (16.3)1
ase.21 (28.1%), 492 of 1695 (29.0%), and 3461 of 14 835
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M. Stern et al.117223.3%). Frequency of DR15 in the patient cohort was
omparable: of the 192 individuals included in this
tudy, 43 (22.4%) were DR15 positive (P  .61 versus
ontrol cohorts).
verall Survival
After a median follow-up of 31 months, 120 of
he 192 patients (62%) were alive as of October
005. Kaplan-Meier estimation of 5-year survival
robability showed a signiﬁcantly higher survival
or DR15-positive patients (76%; 95% conﬁdence
nterval, 63%-89%) than for DR15-negative pa-
ients (55%; 95% conﬁdence interval, 47%-64%;
 .04,; Figure 1).
RM and TRM
The estimated 5-year probability of dying from
elapse or disease progression was signiﬁcantly lower
n DR15-positive (5%; 95% conﬁdence interval, 1%-
0%) than in DR15-negative patients (24%; 95%
onﬁdence interval, 17%-33%; P  .02; Figure 2),
hereas no difference was seen in risk of dying from
RM (19%; 95% conﬁdence interval, 10%-35% for
R15-positive patients versus 21%; 95% conﬁdence
nterval, 15%-29% for DR15-negative patients; P 
75; Figure 2).
The protective effect of DR15 on death from
elapse was seen in patients with myeloid (4% versus
2%) and lymphoid (5% versus 29%) malignancies
like. Patients with acute leukemia had higher rates of
eath from relapse than did those with chronic
eukemia/lymphoma; however, lower rates of DRM
or DR15-positive patients were seen in both groups
9% versus 31% for acute leukemia and 0% versus
3% for chronic leukemia/lymphoma).
raft-versus-Host Disease
Acute GVHD was less severe and less frequent in
igure 1. Kaplan-Meier probability of overall survival for DR15-
ositive and DR15-negative patients.R15-positive patients than in DR15-negative pa- tients, but the difference did not reach statistical sig-
iﬁcance. Incidence of aGVHD grade II or greater
as 37% (95% conﬁdence interval, 25%-55%) for
R15-positive patients versus 48% (95% conﬁdence
nterval, 40%-57%) for DR15-negative patients (P 
18; Figure 3). When comparing GVHD rates in my-
loid versus lymphoid malignancies, no difference was
bserved in patients with acute myeloid leukemia and
hose with chronic myeloid leukemia patients (48%
ersus 44% for DR15-positive and DR15-negative
atients, respectively; P  .87), whereas in patients
ith lymphoid malignancies, aGVHD was more fre-
uent in DR15-negative than in DR15-positive pa-
ients (54% versus 25%; P  .03).
One-hundred sixty-seven patients survived 100
ays after transplantation and were thus evaluable for
GVHD. A statistical trend was seen for lower inci-
ence and severity of cGVHD in DR15-positive com-
ared with DR15 negative patients (33% versus 52%;
 .06; Table 2).
igure 2. Cumulative incidence of DRM and TRM in DR15-
ositive and DR15-negative patients.
igure 3. Cumulative incidence of aGVHD of at least grade II in
R15-positive and DR15-negative patients. Post-Tx indicates afterreatment.
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HLA-DR15 Reduces Relapse Risk after HSCT 1173ultivariate Analyses
Multivariate analyses conﬁrmed the results ob-
ained in univariate mode: risk of death from any cause
fter transplantation was smaller for DR15-positive
atients (relative risk versus DR15-negative patients,
.48; 95% conﬁdence interval, 0.25-0.94; P  .03).
ther risk factors emerging as having a negative effect
n overall survival were bad-risk cytogenetics in pa-
ients with acute leukemia and conditioning with
usulfan/cyclophosphamide (Table 3). The latter
nding must be seen in light of our practice of apply-
ng this conditioning regimen to patients not eligible
or total body irradiation, in most instances because of
xtensive pretreatment including prior total body ir-
adiation, eg, for autologous transplantation.
When restricting the analysis to death from
elapse/progression, DR15 positivity emerged as a
rotective factor (relative risk versus DR15 negativity,
.16; 95% conﬁdence interval, 0.04-0.68; P  .01;
able 3). Other risk factors associated with an in-
reased risk of death from relapse were advanced stage
nd bad-risk cytogenetics. In contrast, TRM was not
igniﬁcantly inﬂuenced by DR15 status (relative risk
or DR15 positive versus negative, 0.91; 95% conﬁ-
ence interval, 0.42-1.95; P  .81; Table 3); the only
ariable with a signiﬁcant effect was date of transplan-
ation, with a higher risk for patients who underwent
ransplantation before 2000 and the highest risk for
hose who underwent transplantation before 1995.
ISCUSSION
The presence of DR15 inﬂuences outcome after T
ell-replete HLA-identical sibling HSCT for hemato-
ogic malignancies; mortality from relapse/disease pro-
ression was signiﬁcantly lower in carriers of the antigen
han in DR15-negative patients. No difference was seen
hen comparing the 2 groups for TRM. The lower
ikelihood of dying from relapse after HSCT translated
nto a signiﬁcant overall survival advantage for DR15-
ositive patients. Protection from disease relapse occurs
ithout an increase in incidence or severity of GVHD,
rguing for a graft-versus-leukemia effect targeted spe-
iﬁcally against hematopoietic cells.
Our results stand in contrast to those from a recent
able 2. Incidence of Chronic Graft-versus-Host Disease
DR15 Negative DR15 Positive P  .11*
o cGVHD 63 (49.2%) 26 (66.7%) P  .06†
imited cGVHD 24 (18.8%) 3 (7.7%)
xtensive cGVHD 41 (32.0%) 10 (25.6%)
GVHD indicates chronic graft-versus-host disease.
P value overall.
P value for no cGVHD versus limited/extensive combined.etrospective single-center report from Roswell Parkancer Institute by Battiwalla et al [12], which had found
decreased incidence of aGVHD for DR15-positive
atients without any difference in rates of relapse or
verall survival. Differences in the transplantation pro-
edure and several disparities between our cohort and
he Roswell Park patients might explain the discrepant
ndings.
In the Roswell Park cohort, the vast majority of
atients received bone marrow stem cells, with almost
0% of patients receiving triple-agent GVHD prophy-
able 3. Multivariate Analyses for Risk of Death, for
elapse/Progression Mortality, and for Non-relapse Mortality
Risk factor RR 95% CI P
eath from any cause*
DR15 status
Negative 1.00 — —
Positive 0.48 0.25-0.94 .03
Cytogenetics .009
Good risk 1.00 — —
Intermediate risk 2.54 0.75-8.58 .13
Bad risk 3.89 1.06-14.3 .04
Conditioning .01
Cyclophosphamide/TBI 1.00 — —
Cyclophosphmamide/TBI/VP16 2.05 0.80-5.24 .13
Busulfan/cyclophosphamide 4.36 1.25-15.2 .02
Fludarabine/TBI 1.83 0.58-5.80 .30
Other 6.10 2.00-18.8 .002
eath from disease
relapse/progression†
DR15 status
Negative 1.00 — —
Positive 0.16 0.04-0.68 .01
Cytogenetics .04
Good risk 1.00 — —
Intermediate risk 4.43 0.58-34.7 .15
Bad risk 12.0 1.25-114 .03
Disease stage
Early 1.00 — —
Advanced 3.20 1.49-6.88 0.003
onrelapse mortality‡
DR15 status
Negative 1.00 — —
Positive 0.91 0.42-1.95 .81
Date of transplantation .005
After 2000 1.00 — —
Before 1995 3.92 1.69-9.10 .001
1995-2000 2.29 1.00-5.21 .05
R indicates risk ratio; CI, conﬁdence interval; TBI, total body
irradiation.
Pretransplantation variables without a statistically signiﬁcant effect on
survival are disease stage, disease, patient age, donor/recipient sex
combination, date of transplantation, and graft-versus-host disease
prophylaxis.
Pretransplantation variables without a statistically signiﬁcant effect on
survival are patient age, disease, conditioning, donor/recipient sex
combination, date of transplantation, and graft-versus-host disease
prophylaxis.
Pretransplantation variables without a statistically signiﬁcant effect on
survival are disease, disease stage, cytogenetics, donor/recipient sex
combination, patient age, conditioning, and graft-versus-host dis-
ease prophylaxis.
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M. Stern et al.1174axis, whereas most of our patients were treated with
eripheral blood stem cells and received 3-agent GVHD
rophylaxis at a maximum, with these 2 factors possibly
llowing for a stronger manifestation of graft-versus-
eukemia effects. Other factors possibly explaining the
ifferential outcome in the Roswell Park cohort include
nclusion of patients who received transplants from un-
elated donors and the use of serologic typing methods
n a subgroup of patients, whereas all individuals in our
ohort received transplants from HLA-genoidentical
iblings and were HLA typed using molecular methods.
registry study including a large homogeneous patient
opulation would clearly help to resolve the discrepan-
ies seen in outcome between our present report and the
tudy by Battiwalla et al.
This ﬁrst report on the presence of an HLA anti-
en inﬂuencing relapse rate and survival after HLA-
dentical sibling HSCT raises several questions.
If the presence of DR15 confers a preferential
ntileukemic effect, lower intensity conditioning reg-
mens might be sufﬁcient to produce donor chimerism
nd eradicate leukemia in patients carrying the anti-
en. Although only a minority of patients received
onmyeloablative conditioning regimens (33 of 192)
n the present study, survival rates of DR15-positive
ersus DR15-negative patients (100% versus 66%)
eem to conﬁrm this hypothesis. More extensive stud-
es on DR15 status in patients receiving reduced in-
ensity conditioning seem warranted.
Another question concerns the mechanism of ac-
ion and its tissue speciﬁcity: in patients who have not
ndergone transplantation, apart from its association
ith autoimmune cytopenia, DR15 has been linked to
ncreased susceptibility to a host of autoimmune dis-
ases such as multiple sclerosis [22], systemic lupus
rythematodes [23], Goodpasture syndrome [24], sar-
oidosis [25] , uveitis [26], and ulcerative colitis [27].
owever, after transplantation, the presence of DR15
eems to have an inhibitory effect on GVHD, if at all;
he incidence of aGVHD of at least grade II was lower
n our cohort and the cohort reported by Battiwalla
t al. In light of the association of DR15 with auto-
mmune cytopenia, if interpreted as a collateral dam-
ge effect of the immune system attacking the
alignant clone, it is intriguing to hypothesize that
onor-versus-recipient alloreactions against DR15
ight also extend beyond the malignant clone and
fﬁciently eradicate residual donor antigen-presenting
ells, which have been thought responsible for initiat-
ng aGVHD [28]. Increased susceptibility of DR15-
ositive host hematopoietic derived cells to donor-
ersus-recipient alloreactivity might thus explain the
ower relapse rate and protection from GVHD.
Mismatches in minor histocompatibility antigens
estricted to DR15 would constitute an alternative
xplanation of DR15 effects on GVHD and graft-
ersus-leukemia disease. Of the known minor histo-ompatibility antigens, RPS4Y1 has been shown to be
estricted to DRB1*1501 [29]. The corresponding
ene is located on the Y chromosome, implicating an
ffect only in male patients. However, in our cohort,
ale and female DR15-positive patients had superior
urvival, and no interaction between DR15 status and
onor gender was seen in multivariate analysis.
Concerning the mechanism of action, the very
trong linkage disequilibrium of DRB1*1501-DRB5*-
101-DQB1*0602 alleles in Caucasoids means that the
ocus involved in the response could be DRB1, DRB5,
r DQB1 or a non-HLA gene linked to this haplo-
ype. Transfection of leukemic HLA-deﬁcient cell
ines with different HLA class II antigens [30] might
hed further light on the contribution of single HLA
ntigens on evoking an allogeneic immune response.
ur report has several limitations: the study popula-
ion was heterogeneous for underlying disease, condi-
ioning regimen, and GVHD prophylaxis. However,
nown pretransplantation risk factors and treatment
egimens were evenly distributed among DR15-positive
nd -negative patients. The strength of the study lies in
he fact that only patients who received transplants
rom HLA-genoidentical sibling donors were in-
luded and that all patients had undergone molecular
LA DRB1* typing. In conclusion, our report shows
n association of DR15 with decreased disease relapse
nd increased survival in patients treated with HSCT
or leukemia or non-Hodgkin lymphoma. These data
dd to the growing list associatingDR15with immune-
ediated events in hematopoiesis. They suggest that
R15 could mitigate a graft-versus-leukemia effect
fter HSCT without increasing the incidence of
VHD.
CKNOWLEDGMENTS
This work was supported by research grants from
he Swiss Cancer League (grant BIL OCS 01597-08-
004) and the Swiss National Science Foundation
grant PBBSB-107328).
EFERENCES
1. Chapuis B, Von Fliedner VE, Jeannet M, et al. Increased fre-
quency of DR2 in patients with aplastic anaemia and increased DR
sharing in their parents. Br J Haematol. 1986;63:51-57.
2. Nimer SD, Ireland P, Meshkinpour A, Frane M. An increased
HLA DR2 frequency is seen in aplastic anemia patients. Blood.
1994;84:923-927.
3. Kapustin SI, Popova TI, Lyschov AA, Togo AV, Abdulkadyrov
KM, Blinov MN. HLA-DR2 frequency increase in severe
aplastic anemia patients is mainly attributed to the prevalence of
DR15 subtype. Pathol Oncol Res. 1997;3:106-108.
4. Ihan O, Beksac M, Arslan O, et al. HLA DR2: a predictive
marker in response to cyclosporine therapy in aplastic anemia.
Int J Hematol. 1997;66:291-295.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
HLA-DR15 Reduces Relapse Risk after HSCT 11755. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15
(DR2) is overrepresented in myelodysplastic syndrome and
aplastic anemia and predicts a response to immunosuppression
in myelodysplastic syndrome. Blood. 2002;100:1570-1574.
6. Nakao S, Takamatsu H, Chuhjo T, et al. Identiﬁcation of a
speciﬁc HLA class II haplotype strongly associated with sus-
ceptibility to cyclosporine-dependent aplastic anemia. Blood.
1994;84:4257-4261.
7. Maciejewski JP, Follmann D, Nakamura R, et al. Increased
frequency of HLA-DR2 in patients with paroxysmal nocturnal
hemoglobinuria and the PNH/aplastic anemia syndrome. Blood.
2001;98:3513-3519.
8. Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett
AJ. A simple method to predict response to immunosuppressive
therapy in patients with myelodysplastic syndrome. Blood. 2003;
102:3025-3027.
9. Feng X, Chuhjo T, Sugimori C, et al. Diazepam-binding in-
hibitor-related protein 1: a candidate autoantigen in acquired
aplastic anemia patients harboring a minor population of par-
oxysmal nocturnal hemoglobinuria-type cells. Blood. 2004;104:
2425-2431.
0. Clark RE, Hermans J, Madrigal A, et al. HLA-A3 increases
and HLA-DR1 decreases the risk of acute graft-versus-host
disease after HLA-matched sibling bone marrow transplan-
tation for chronic myelogenous leukaemia. Br J Haematol.
2001;114:36-41.
1. Remberger M, Persson U, Hauzenberger D, Ringden O. An
association between human leucocyte antigen alleles and acute and
chronic graft-versus-host disease after allogeneic haematopoietic
stem cell transplantation. Br J Haematol. 2002;119:751-759.
2. Battiwalla M, Hahn T, Radovic M, et al. Human leukocyte anti-
gen (HLA) DR15 is associated with reduced incidence of acute
GVHD in HLA-matched allogeneic transplantation but does not
impact chronic GVHD incidence. Blood. 2006;107:1970-1973.
3. Grimwade D, Walker H, Oliver F, et al. The importance of
diagnostic cytogenetics on outcome in AML: analysis of 1,612
patients entered into the MRC AML 10 trial. The Medical
Research Council Adult and Children’s Leukaemia Working
Parties. Blood. 1998;92:2322-2333.
4. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical signif-
icance of cytogenetic abnormalities in adult acute lymphoblastic
leukemia. Blood. 1998;91:3995-4019.
5. Müller C, Goldmann S, Wegener S. German normal. In: Gjertson
D, Terasaki P, eds. HLA 1998. Lenexa, Kan: ASHI; 1998:154-155.
6. Schwartz K, Woelpl A, Spegel J, Müller C, Goldmann S.
Caucasian German normal. In: Gjertson D, Terasaki P, eds.
HLA 1998. Lenexa, Kan: ASHI; 1998:149.7. Tiercy J-M, Grundschober C, Jeannet M. Causasian Swiss
normal. In: Gjertson D, Terasaki P, eds. HLA 1998. Lenexa,
Kan: ASHI; 1998;189.
8. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations
of graft-versus-host disease in human recipients of marrow
from HL-A-matched sibling donors. Transplantation. 1974;18:
295-304.
9. Kaplan EL, Meier P. Nonparametric estimation from incom-
plete observations. J Am Stat Assoc. 1958;53:457-481.
0. Cox DR. Regression models and life tables. J R Stat Soc. 1972;
34B:187-220.
1. Fine J, Gray R. A proportional hazards model for the subdis-
tribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
2. Prat E, Tomaru U, Sabater L, et al. HLA-DRB5*0101 and
-DRB1*1501 expression in the multiple sclerosis-associated
HLA-DR15 haplotype. J Neuroimmunol. 2005;167:108-119.
3. Cortes LM, Baltazar LM, Lopez-Cardona MG, et al. HLA
class II haplotypes in Mexican systemic lupus erythematosus
patients. Hum Immunol. 2004;65:1469-1476.
4. Phelps RG, Turner AN, Rees AJ. Direct identiﬁcation of nat-
urally processed autoantigen-derived peptides bound to HLA-
DR15. J Biol Chem. 1996;271:18549-18553.
5. Voorter CE, Drent M, van den Berg-Loonen EM. Severe
pulmonary sarcoidosis is strongly associated with the haplo-
type HLA-DQB1*0602-DRB1*150101. Hum Immunol. 2005;
66:826-835.
6. Tang WM, Pulido JS, Eckels DD, Han DP, Mieler WF,
Pierce K. The association of HLA-DR15 and intermediate
uveitis. Am J Ophthalmol. 1997;123:70-75.
7. De La Concha EG, Fernandez-Arquero M, Santa-Cruz S, et al.
Positive and negative associations of distinct HLA-DR2 sub-
types with ulcerative colitis (UC). Clin Exp Immunol. 1997;108:
392-395.
8. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of
graft versus host disease by inactivation of host antigen-pre-
senting cells. Science. 1999;285:412-415.
9. Goulmy E. Minor histocompatibility antigens: from transplan-
tation problems to therapy of cancer. Hum Immunol. 2006;67:
433-438.
0. Weichold FF, Jiang YZ, Dunn DE, et al. Regulation of a
graft-versus-leukemia effect by major histocompatibility com-
plex class II molecules on leukemia cells: HLA-DR1 expression
renders K562 cell tumors resistant to adoptively transferred
lymphocytes in severe combined immunodeﬁciency mice/
nonobese diabetic mice. Blood. 1997;90:4553-4558.
